Across a wide range of specialties, the unique features of minimally invasive surgery provides a consistent array of beneifts to patients, and orthopedic surgeons have worked hard over the past several years to reduce the size of incisions in hip and knee replacement. Skeptics argue that, given the extremely high success rates of conventional hip and knee replacement surgery, any movement toward MIS should be slow and should look beyond patient appeal to focus on long-term results. For MIS leader Zimmer, the bet on the new technique is a big one. The widespread adoption of MIS in orthopedics is less about the transformation of a procedure than about the transformation of a company and an industry.
by David Cassak
Over the past two decades, minimally invasive approaches to surgery have transformed a number of surgical specialties, including general surgery...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.
Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.